The initial shipment of medicinal cannabis oils from Endoca will be accessible to patients and healthcare professionals in Australia through the Medicinal Cannabis Medicines Portal (MCMP).
The MCMP (www.mcmp.com.au) significantly streamlines the process required for doctors to prescribe medicinal cannabis to Australian patients via the Special Access Scheme.
Supply will start within weeks
THC has permits in place to begin distributing medicinal cannabis products from Endoca. Australian patients will have access under the Special Access Scheme or through an Approved Prescriber.
Supply will be available in the market within weeks.
The import of these products represents a significant development in advancing the medicinal cannabis industry in Australia, and most importantly, making high quality products available to patients in need.
THC chairman Steven Xu said: “THC’s program to bring Endoca products to Australia is the first step in providing Australia with high quality medicinal cannabis solutions, which will extend to local organic growing and pharmaceutical GMP manufacture as we roll out our partner and domestic production strategy.”
THC also stands to gain from the C-45 Bill that has been passed by Canada’s senate on June 7 to legalise adult recreational use of cannabis in Canada.
Canada is the largest developed nation to legalise nationwide recreational use for adults over the age of 18.
The Cannabis Act is a milestone toward the end of prohibition of recreational cannabis in Canada and is expected to be an important driver of growth for THC’s hydroponics division.